Title

Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients

Document Type

Journal Article

Publisher

BioMed Central Ltd.

Place of Publication

United Kingdom

RAS ID

School of Medical and Health Sciences

Comments

Originally published as: McEvoy, A. C., Warburton, L., Al-Ogaili, Z., Celliers, L., Calapre, L., Pereira, M. R., ... & Gray, E. S. (2018). Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients. BMC cancer, 18(1), 726. Original article available here.

Abstract

Background: Circulating tumour DNA (ctDNA) may serve as a measure of tumour burden and a useful tool for non-invasive monitoring of cancer. However, ctDNA is not always detectable in patients at time of diagnosis of metastatic disease. Therefore, there is a need to understand the correlation between ctDNA levels and the patients' overall metabolic tumour burden (MTB). Methods: Thirty-two treatment naïve metastatic melanoma patients were included in the study. MTB and metabolic tumour volume (MTV) was measured by 18F-fluoro-D-glucose positron emission tomography/computed tomography (FDG PET/CT). Plasma ctDNA was quantified using droplet digital PCR (ddPCR). Results: CtDNA was detected in 23 of 32 patients. Overall, a significant correlation was observed between ctDNA levels and MTB (p<0.001). CtDNA was not detectable in patients with an MTB of ≤10, defining this value as the lower limit of tumour burden that can be detected through ctDNA analysis by ddPCR. Conclusions: We showed that ctDNA levels measured by ddPCR correlate with MTB in treatment naïve metastatic melanoma patients and observed a limit in tumour size for which ctDNA cannot be detected in blood. Nevertheless, our findings support the use of ctDNA as a non-invasive complementary modality to functional imaging for monitoring tumour burden.

DOI

10.1186/s12885-018-4637-6

Access Rights

free_to_read

Share

 
COinS